Antitumor Activity of Single Agent Lurbinectedin in Patients with Relapsed SCLC Occurring >= 30 Days After Last Platinum Dose
J. M. Trigo Perez,V. Subbiah,B. Besse,V. Moreno,R. Lopez,M. A. Sala,S. Ponce, C. Fernendez,A. Nieto,C. Kahatt,A. Zeaiter,K. Zaman,V. Boni,J. Arrondeau,M. Martinez,J. Delord,A. Awada,R. Kristeleit,F. Longo,J. Sarantopoulos,M. Rubio,A. Anton,L. Wannesson,J. Valdivia, G. Shappiro,V. Villalobos, A. Santoro,M. D'Arcangelo,L. Aparicio, L. Paz-Ares JOURNAL OF THORACIC ONCOLOGY（2019）
关键词
SCLC,second line,Lurbinectedin
AI 理解论文
溯源树
样例
